8-K: INVO Fertility Adjourns Key Share Increase Vote, Elects Directors and Approves Conversions at Annual Meeting

INVO Fertility, Inc. held its 2025 annual meeting, electing all director nominees and approving several stock issuance proposals, but adjourned a critical vote to increase authorized common stock until July 9, 2025, to solicit further votes.

Summary

• INVO Fertility, Inc. held its 2025 annual meeting of stockholders on June 25, 2025, with 842,876 shares represented, constituting a quorum.
• The meeting was adjourned regarding Proposal 3, which sought to increase the number of authorized common shares from 4,166,666 to 50,000,000, to allow for further vote solicitation.
• The adjourned meeting for Proposal 3 is rescheduled for Wednesday, July 9, 2025, at 12:00 pm Eastern Time, to be held virtually.
• All five director nominees (Trent Davis, Rebecca Messina, Barbara Ryan, Steven Shum, and Matthew Szot) were elected to the Board of Directors.
• Stockholders ratified the appointment of M&K CPAs PLLC as the independent public accountant for the fiscal year ending December 31, 2025, with 779,963 votes for.
• Approval was granted for the issuance of common stock upon conversion of outstanding Series C-2 Non-Voting Convertible Preferred Stock, with 222,410 votes for.
• Approval was granted for the issuance of common stock upon conversion of an outstanding 7.0% Senior Secured Convertible Debenture with a principal balance of $4,803,175 due February 11, 2026, with 229,971 votes for.
• Approval was granted for the issuance of common stock upon conversion of outstanding warrants issued pursuant to an inducement letter agreement dated April 30, 2025, with 223,551 votes for.
• The third amendment and restatement of the Company's 2019 Stock Incentive Plan was approved, increasing shares available for issuance to 1,200,000, approximately 10% of total issued and outstanding stock on a fully-diluted basis, with 248,324 votes for.
• Stockholders approved, by non-binding advisory vote, the resolution regarding named executive officer compensation, with 219,381 votes for.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While most proposals passed, the critical adjournment of the authorized share increase (Proposal 3) is a significant setback that could impact future financing flexibility. The need to solicit more votes suggests a lack of strong shareholder alignment on a key strategic item.

Positives

• All five director nominees were successfully elected, ensuring continuity in board leadership.
• The appointment of M&K CPAs PLLC as the independent public accountant for fiscal year 2025 was ratified, maintaining financial oversight.
• Shareholders approved the conversion of Series C-2 Preferred Stock, a 7.0% Senior Secured Convertible Debenture ($4,803,175 principal), and Inducement Warrants into common stock, which can simplify the capital structure and reduce debt/preferred obligations.
• The 2019 Stock Incentive Plan was amended to increase shares available for issuance to 1,200,000, which can facilitate employee retention and motivation through equity incentives.
• The non-binding advisory vote on named executive officer compensation passed, indicating shareholder alignment with current compensation practices.

Negatives

• The critical Proposal 3, seeking to increase authorized common stock from 4,166,666 to 50,000,000 shares, was not approved and required an adjournment of the annual meeting to solicit further votes. This indicates a lack of sufficient shareholder support for a significant capital structure change.

Risks

• Failure to approve the increase in authorized common stock (Proposal 3) could limit the Company's flexibility in future capital raises, strategic transactions (e.g., mergers, acquisitions), or equity-based compensation plans, potentially hindering growth or financial stability.
• The need to adjourn the meeting to solicit more votes for Proposal 3 suggests potential shareholder dissent or apathy regarding a key strategic initiative, which could signal broader governance challenges.

Future Outlook

The Company has adjourned its annual meeting to July 9, 2025, to continue soliciting votes for a critical proposal to increase its authorized common stock. This indicates a strategic intent to expand its share base, likely for future financing or corporate development activities. The approval of various conversion proposals suggests an ongoing effort to manage and simplify its capital structure.

Management Comments

• The Annual Meeting was adjourned to further solicit votes to approve the amendment to the Companys Amended and Restated Articles of Incorporation to increase its number of authorized shares of common stock from 4,166,666 to 50,000,000.
• Steven Shum, Chief Executive Officer, signed the report on behalf of INVO FERTILITY, INC.

Industry Context

This filing primarily concerns corporate governance and capital structure management within INVO Fertility, Inc., a company likely operating in the fertility or healthcare sector given its name. The need to increase authorized shares is a common corporate action, often preceding capital raises or strategic growth initiatives, which are prevalent across various industries, including healthcare, to fund research, expansion, or acquisitions. The approval of conversions of preferred stock and debentures reflects typical financial management strategies to streamline debt and equity.

Comparison to Industry Standards

• This document does not provide financial performance data that would allow for a direct comparison to industry-specific financial benchmarks or competitor results.
• The corporate governance actions, such as director elections and auditor ratification, are standard practices for publicly traded companies.
• The attempt to significantly increase authorized shares is a common mechanism used by growth-oriented companies, particularly in sectors requiring substantial capital, though the adjournment suggests a challenge in achieving immediate shareholder consensus compared to companies that pass such proposals smoothly.
• No specific comparable companies or projects are mentioned in the document.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The adjournment of the authorized share increase proposal could create uncertainty regarding future capital structure and potential dilution. The approval of conversions of preferred stock and debentures into common stock could lead to increased share count. The approval of the stock incentive plan amendment allows for more equity-based compensation, potentially diluting existing shareholders but also incentivizing employees.
• Employees: The approval of the increased share pool for the 2019 Stock Incentive Plan provides more opportunities for equity-based compensation, potentially enhancing employee retention and motivation.
• Creditors: The approval of the conversion of the 7.0% Senior Secured Convertible Debenture into common stock would reduce the company's debt obligations, potentially improving its financial health from a creditor's perspective.

Next Steps

• The adjourned annual meeting will reconvene on Wednesday, July 9, 2025, at 12:00 pm Eastern Time, virtually, to further solicit votes for Proposal 3.

Key Dates

Recommendation

Keywords

INVO Fertility, SEC filing, 8-K, Annual Meeting, Stockholders Meeting, Corporate Governance, Shareholder Vote, Authorized Shares, Common Stock, Convertible Preferred Stock, Convertible Debenture, Stock Incentive Plan, Executive Compensation, Nasdaq Listing Rule 5635, IVF